INDICATION

BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy. ...read more

The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit.

Introducing support, simplified

Discover how Amgen Assist® can help refer you to the resources most important to you

Amgen Assist 360™

Call 1-888-4ASSIST (1-888-427-7478) to speak to an Amgen Nurse Navigator, Monday–Friday 9 AM–8 PM ET.

  • * For those with English as a second language, Amgen Nurse Navigators are able to connect you with a personal interpreter to help

Amgen Nurse Navigators

Amgen Nurse Navigators are a single point of contact who take the time to help you and your caregiver identify which types of assistance are most important to you. They will assist you in finding resources, so that you and your caregiver can focus on your treatment. They do not, however, provide medical advice or case management services.*

Co-pay and reimbursement resources

Whatever insurance you have—even if you have none—the Amgen Nurse Navigator can help you understand how your Amgen medicine may be covered and refer you to programs that may be able to help you afford it, such as Amgen FIRST STEP or other independent nonprofit organizations.

Referrals to resources for day-to-day living

Sometimes you need someone who knows what you’re going through. The Amgen Nurse Navigator can refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.

Help finding transportation and lodging assistance

If you need assistance with travel that’s connected to your therapy, the Amgen Nurse Navigator can put you in touch with independent nonprofit organizations that may provide you help with gas, tolls, parking, airfare, and lodging.

Medication answers

If you have any questions about your Amgen medicine, the Amgen Nurse Navigator may help you find the answers.

Learn more about Amgen Assist®

*Patients should always talk to their health care provider about any medical decisions or concerns they may have.
Provided through independent nonprofit patient assistance programs; program eligibility is based on the nonprofit’s criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Resources for you and your caregiver

Resources in Spanish are now available
BLINCYTO® (blinatumomab)

BLINCYTO® brochure

A resource for patients and their caregivers, this brochure contains information on BLINCYTO®, how it can help, and what to expect on the treatment journey.

Download English Version

Download Spanish Version

BLINCYTO® (blinatumomab)

Pediatric patient brochure

A resource for pediatric patients and their caregivers on what BLINCYTO® does, how it works, and what to expect during treatment.

Download English Version

Download Spanish Version

BLINCYTO® (blinatumomab)

Medical information card

Fill out this medical information card. You can keep your important health care contact information in one place here.

Download English Version

Download Spanish Version

BLINCYTO® (blinatumomab)

Remember, you are not alone

Are you familiar with these groups and organizations? They offer valuable resources and support that may be right for you or your loved one.

  • The Leukemia & Lymphoma Society can be found at lls.org
  • Reach out to the American Cancer Society at cancer.org
  • Adolescents and young adults may want to check out stupidcancer.org

Important Safety Information

What is the most important information I should know about BLINCYTO®?

  • Call your health care provider or get emergency medical help right away if you get any of the symptoms listed below:
    • BLINCYTO® may cause serious side effects that can be severe, life-threatening, or lead to death, including:
      • Cytokine Release Syndrome (CRS) and infusion reactions. Symptoms of CRS and infusion reactions may include: fever, tiredness or weakness, dizziness, headache, low blood pressure, nausea, vomiting, chills, face swelling, wheezing or trouble breathing, and skin rash.
      • Neurologic problems. Symptoms of neurologic problems may include: seizures, difficulty in speaking or slurred speech, loss of consciousness, trouble sleeping, confusion and disorientation, loss of balance, headache, and difficulty with facial movements, hearing, vision, or swallowing.
    • Your health care provider will check for these problems during treatment with BLINCYTO®. Your health care provider may temporarily or completely stop your treatment with BLINCYTO® if you have severe side effects.

Who should not receive BLINCYTO®?

  • Do not receive BLINCYTO® if you are allergic to blinatumomab or to any of the ingredients of BLINCYTO®.

What should I avoid while receiving BLINCYTO®?

  • Do not drive, operate heavy machinery, or do other dangerous activities while you are receiving BLINCYTO® because BLINCYTO® can cause neurological symptoms such as dizziness, seizures, and confusion.

Before receiving BLINCYTO®, tell your health care provider about all of your medical conditions, including if you or your child:

  • have a history of neurological problems, such as seizures, confusion, trouble speaking or loss of balance
  • have an infection
  • have ever had an infusion reaction after receiving BLINCYTO® or other medications
  • have a history of radiation treatment to the brain, or chemotherapy treatment
  • are scheduled to receive a vaccine. You should not receive a “live vaccine” within 2 weeks before you start treatment with BLINCYTO®, during treatment, and until your immune system recovers after you receive your last cycle of BLINCYTO®. If you are not sure about the type of vaccine, ask your health care provider.
  • are pregnant or plan to become pregnant. BLINCYTO® may harm your unborn baby. Tell your health care provider if you become pregnant during treatment with BLINCYTO®.
    • If you are able to become pregnant, your health care provider should do a pregnancy test before you start treatment with BLINCYTO®.
    • Females who are able to become pregnant should use an effective form of birth control during treatment with BLINCYTO®, and for 48 hours after the last dose of BLINCYTO®.
  • are breastfeeding or plan to breastfeed. It is not known if BLINCYTO® passes into your breast milk. You should not breastfeed during treatment with BLINCYTO® and for 48 hours after your last treatment.
  • Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
  • BLINCYTO® may cause serious side effects, including:
    • Infections. BLINCYTO® may cause life-threatening infections that may lead to death. Tell your health care provider right away in case you develop any signs or symptoms of an infection.
    • Low white blood cell counts (neutropenia). Neutropenia is common with BLINCYTO® treatment and may sometimes be life-threatening. Low white blood cell counts can increase your risk of infection. Your health care provider will do blood tests to check your white blood cell counts during treatment with BLINCYTO®. Tell your health care provider right away if you get a fever.
    • Abnormal liver blood test. Your health care provider will do blood tests to check your liver before you start BLINCYTO® and during treatment with BLINCYTO®.
    • Inflammation of the pancreas (pancreatitis). Pancreatitis may happen in patients treated with BLINCYTO® and corticosteroids. It may be severe and lead to death. Tell your health care provider right away if you have severe abdominal pain that does not go away. The pain may happen with or without nausea and vomiting.
  • Your health care provider will do blood tests during treatment to check for side effects.
  • The most common side effects of BLINCYTO® include:
    • Infections
    • Fever
    • Headache
    • Low red blood cell count (anemia)
    • Low white blood cell count (neutropenia)
    • Low white blood cell count with fever (febrile neutropenia)
    • Low platelet count (thrombocytopenia)
    • Reactions related to infusion of the medicine such as face swelling, low blood pressure, and high blood pressure (infusion-related reactions)
  • These are not all the possible side effects of BLINCYTO®.
  • Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • Please read the accompanying Medication Guide before you or your child receives BLINCYTO® and before each BLINCYTO® infusion and discuss it with your doctor.

INDICATION

BLINCYTO® (blinatumomab) is a prescription medicine used to treat B-cell precursor acute lymphoblastic leukemia (ALL) in patients who still have detectable traces of cancer after chemotherapy.

The approval of BLINCYTO® in these patients is based on a study that measured response rate and duration of response. There are ongoing studies to confirm clinical benefit.

Important Safety Information

What is the most important information I should know about BLINCYTO®?

  • Call your health care provider or get emergency medical help right away if you get any of the symptoms listed below:
    • BLINCYTO® may cause serious side effects that can be severe, life-threatening, or lead to death, including:
      • Cytokine Release Syndrome (CRS) and infusion reactions. Symptoms of CRS and infusion reactions may include: fever, tiredness or weakness, dizziness, headache, low blood pressure, nausea, vomiting, chills, face swelling, wheezing or trouble breathing, and skin rash.
      • Neurologic problems. Symptoms of neurologic problems may include: seizures, difficulty in speaking or slurred speech, loss of consciousness, trouble sleeping, confusion and disorientation, loss of balance, headache, and difficulty with facial movements, hearing, vision, or swallowing.
  • Your health care provider will check for these problems during treatment with BLINCYTO®. Your health care provider may temporarily or completely stop your treatment with BLINCYTO® if you have severe side effects.